Interestingly, the development of hypertension during bevacizumab therapy is considered a favorable prognosticator, as it denotes the presence of certain “hypertension-susceptible” VEGF polymorphisms (VEGF-2578 AA and VEGF-1154 A) linked to a better response to chemotherapy and increased survival [107]. This evidence concerns the gene VEGFA and hypertensive disorder.